Aerovate Therapeutics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AVTE and other ETFs, options, and stocks.

About AVTE

Aerovate Therapeutics, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension.

CEO

Timothy P. Noyes

CEOTimothy P. Noyes

Employees

Employees51

Headquarters

Waltham, Massachusetts

HeadquartersWaltham, Massachusetts

Founded

2018

Founded2018

Employees

Employees51

AVTE Key Statistics

Market cap

582.22M

Market cap582.22M

Price-Earnings ratio

-7.08

Price-Earnings ratio-7.08

Dividend yield

—

Dividend yield—

Average volume

126.73K

Average volume126.73K

High today

$22.34

High today$22.34

Low today

$19.99

Low today$19.99

Open price

$21.00

Open price$21.00

Volume

99.54K

Volume99.54K

52 Week high

$32.42

52 Week high$32.42

52 Week low

$9.41

52 Week low$9.41

Analyst ratings

100%

of 7 ratings

Buy

100%

Hold

Sell

Aerovate Therapeutics

Why Robinhood?

Aerovate Therapeutics, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. Show more

AVTE Key Statistics

Analyst ratings

100%

Aerovate Therapeutics, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension.